Profil
Frank L.
Porfido held the position of Chief Financial Officer at Tyme Technologies, Inc. in 2021 and Vice President-Finance at UroGen Pharma, Inc. from 2019 to 2021.
He earned an MBA from Fairleigh Dickinson University and an undergraduate degree from Pace University.
Anciens postes connus de Frank L. Porfido
| Sociétés | Poste | Fin |
|---|---|---|
| TYME TECHNOLOGIES, INC. | Director of Finance/CFO | 16/09/2022 |
| UroGen Pharma, Inc. | Corporate Officer/Principal | 01/05/2021 |
Formation de Frank L. Porfido
| Fairleigh Dickinson University | Masters Business Admin |
| Pace University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Tyme Technologies, Inc.
 Tyme Technologies, Inc. Pharmaceuticals: MajorHealth Technology Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ. | Health Technology |
| UroGen Pharma, Inc. | Health Technology |
